Emanuel [email protected]

research leader @IsomorphicLabs 🇨🇭🇩🇪
opinions are my own

[Ankit Gupta @agupta]

https://t.co/mC9HFKBs4q

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development
https://t.co/S5cnzzdZ9M
https://t.co/vZI21gUhII
This new Perspective discusses the value of trial simulations, presents best-practice recommendations and describes case studies of impact

[Emanuel [email protected] @ebioman]

Discovering gravel bikes

[Berci Meskó, MD, PhD @Berci]

The world of cancer is complex, non-linear and the fight against the deadly disease family requires particular attention from care providers.

That’s why the concise, accurate and yet simple infographics created as illustrations for the National Institute for Health and Care Excellence’s latest guidelines for the investigation and referral of suspected cancer cases are pure brilliance.

[Isomorphic Labs @IsomorphicLabs]

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients.
Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine.
Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine.

Read the full announcement here: https://t.co/TtXk3xqA84

[Sergei Yakneen @SergeiIakhnin]

I've finished my 4+ year mission as CTO @IsomorphicLabs and am moving into an Advisory role with the company. Time to prioritize my family and recharge. Hugely grateful to everyone at Iso for the opportunity to build this seminal company together. Semper prorsum!

[Anirban Maitra @Aiims1742]

Super excited to have our simultaneous publication in @CD_AACR concurrent with #AACR26 talk by @MundAndreas @OmicVision on Deep Visual Proteomics (DVP) of #PancreaticCancer precursor lesions, the largest high resolution proteomics dataset of PanIN lesions.
https://t.co/7h4Aae4OOT

[Sergei Yakneen @SergeiIakhnin]

A new blog and technical report (https://t.co/XcxIIN7KED) from @IsomorphicLabs shows SOTA performance across hardest modelling tasks in drug discovery more than twice AF3 level on low similarity protein-ligand, antibody-antigen, and exceeding FEP+ accuracy on binding affinity

[David Ochoa @d0choa]

🚀 Announcing the Official @OpenTargets MCP!
We've partnered with @AnthropicAI to provide AI with seamless access to high-quality genetics and target-discovery data. Open for the entire community to accelerate therapeutic development
https://t.co/bwuw9udxwV

[Nature Reviews Drug Discovery @NatRevDrugDisc]

2025 FDA drug approvals https://t.co/1lIWG9AiF2

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency. Read about the trends and highlights, and see the full list of approved therapeutics in our annual round up

[Emanuel [email protected] @ebioman]

Splendid day

[Isomorphic Labs @IsomorphicLabs]

Next week, our Director of Computational Biology, Melissa Davis, will take part in a panel discussion at the @UKBIOBANK Scientific Conference in London.
Melissa will talk about how Isomorphic Labs is leveraging large-scale data to transform the future of drug discovery. If you can’t join Melissa at the event, register to watch online.
Head to the comments for the link.

[Max Jaderberg @maxjaderberg]

Honoured to be stepping into the role of President at @IsomorphicLabs. We've built an AI drug design engine that we can see day-to-day is leading to more and more breakthroughs in the design of better medicines for patients. But we're just getting started! Excited to work with @demishassabis and our team to drive our mission forward!

[Isomorphic Labs @IsomorphicLabs]

Curious about what it’s like to work at Isomorphic Labs’ Swiss location? In our latest blog post we're taking you inside IsoLabs' Lausanne office to learn about its history and meet some of the Isos based there.
Since opening in 2023, Lausanne has grown into a close-knit hub where data engineers, ML researchers, computational biologists and software engineers work together to solve complex problems every day.
Head to the comments to read the blog!

[Javier Santoyo @jsantoyo]

HI-FEVER: a Nextflow pipeline for the high-throughput discovery and annotation of endogenous viral elements. #EndogenousViralElements #EukaryoticHostGenomes #Genomics #Bioinformatics
https://t.co/PnXKkIRaRc

[Matthias Mann Lab @labs_mann]

Excited to share AlphaDIA's publication in Nature Biotechnology!
Our open-source DIA framework brings deep learning directly to raw MS data with feature-free processing, transfer learning for any PTM, and performance matching top tools.
https://t.co/keoFdUc1lG

[parm🔬 @parmita]

I keep saying “drug discovery” but most of my audience does not understand what this means.

Here’s a thread I worked on over the past week trying to distil down drug discovery - and why it matters in the age of AI.

OPEN THE THREAD 🧵

[Sergei Yakneen @SergeiIakhnin]

Excited to give opening keynote at #BioTechXEurope in Basel on October 6, at 9 AM! I'll share about our progress @IsomorphicLabs and our framework for using ML to model biology across multiple scales, from atoms to humans, to enable rational in-silico drug design. See you there!

[Isomorphic Labs @IsomorphicLabs]

Our Chief Technology Officer, @SergeiIakhnin will be opening @BioTechX_ EU Congress with a keynote at 9am CEST on Monday, 6 October. AI is already helping us to understand disease like never before, but where are we going next? Sergei will explore a future where applying frontier AI unlocks faster breakthroughs and with an ambition to solve all disease. If you are planning to attend, don't miss it. Find out more about the event here: https://t.co/jLDdIpcfh7

[Max Jaderberg @maxjaderberg]

It was great to join our CEO, @demishassabis, and Head of Medicinal Drug Design @_rebecca_paul, on the latest episode of Bloomberg Tech (@technology) with @TomMackenzieTV, to share how we’re approaching building our AI drug design engine from first principles, our vision for the future of drug discovery, and what makes Iso different 1/2